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in Stable Coronary Artery Disease*
Harold L. Dauerman, MDA spirin has been a cornerstone of secondaryprevention in patients with stable coronaryartery disease (CAD) for more than 4 de-
cades. Aspirin targets a speciﬁc pathophysiological
process that is considered fundamental to the
progression from stable to unstable coronary syn-
dromes—platelet activation (1). Aspirin is inexpensive
and easy to use, but it does increase the risk of
bleeding compared with not using antiplatelet ther-
apy (2). Use of aspirin in secondary prevention is
strongly supported by several guidelines, because
the bleeding risk is balanced by prevention of throm-
botic events (3,4).
Thus, it is not surprising that when faced with an
elderly patient with stable CAD, new-onset atrial
ﬁbrillation, and additional oral anticoagulation, we
adhere to a simple mantra: never stop the aspirin.
Recently, investigators have suggested that this
practice puts patients at undue risk of bleeding with
no ischemic beneﬁts (5–7). Thus, is it time to abandon
inhibition of platelet activation in patients with stable
CAD who are on oral anticoagulation?SEE PAGE 1430BLEEDING IN THE CLINIC: INSIGHTS INTO INCIDENCE,
PROGNOSIS, AND PREDICTORS. In this issue of the
Journal, Hamon et al. (8) present CORONOR (Suivi
d’une cohorte de patients COROnariens stables en
region NORd-Pas-de-Calais), a large, multicenter site-
based registry of patients in stable condition with
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infarction in the previous 12 months. This observa-
tional registry provides 2 major insights into a
generally low-risk population. (1) Bleeding Academic
Research Consortium (BARC) bleeds type $3 during 2
years of follow-up is mostly gastrointestinal and oc-
curs in <1% of patients per year. The investigators
called BARC bleeds of types 3, 4, and 5 major
bleeding, which only makes sense if BARC 2 is de-
ﬁnitively proven not to be associated with death (9).
Of note, BARC bleed scales have only been utilized in
the inpatient setting; therefore, the CORONOR study
provides the ﬁrst point estimates of BARC bleeds in
the outpatient setting. (2) BARC major bleeds among
outpatients are similar to major bleeding among in-
patients with CAD in unstable condition; these major
bleeds are associated with more death (10).
The most challenging aspect of this outpatient
observational registry is the question of aspirin in
patients who require oral anticoagulation. The 4
predictors of major bleeding in this study were not
surprising; older age, diabetes, renal failure, and
warfarin were associated with more bleeding (8).
Although some predictors of bleeding common to
inpatients did not show up in this analysis (i.e., fe-
male sex) (11), in general, these ﬁndings are consis-
tent with previous inpatient studies of acute coronary
syndromes. The most powerful predictor of major
bleeding in CAD patients in stable condition is use
of vitamin K antagonists (hazard ratio of 4.7 com-
pared with patients who do not require oral anti-
coagulation). The CORONOR registry suggests that
warfarin does not confer a bleeding risk; rather, the
combination of antiplatelet therapy with warfarin is
the only antithrombotic regimen that independently
predicts bleeding (8). Importantly, continuing aspirin
with warfarin does not demonstrate ischemic beneﬁt
(8). As shown in Table 1, at least 4 studies seem to
provide a clear message (5–7,12): stop worrying
TABLE 1 Addressing the Risk of Aspirin Combined With Oral Anticoagulation
Study
Sample Size
Enrollment Dates Study Design Primary Patient Population
Aspirin Impact on
Ischemic Outcomes Aspirin Impact on Bleeding
CORONOR Registry
(N ¼ 4,184)
2010–2011
Broadly inclusive
European multicenter
site-based registry
Stable CAD: at least 12 months
post-MI or post-
revascularization;
11% on VKA
None
VKA þ APT vs. VKA alone:
Adjusted HR: 1.15
(95% CI: 0.58–2.27)
High risk
Adjusted HR: 7.9 (95% CI: 3.9–13.6)
compared with aspirin without VKA
Danish National Registry
(N ¼ 8,700)
2002–2011
National European
multicenter site-
based registry
Stable CAD with AF
At least 12 months post-
hospitalization for PCI,
MI, or ACS
37% on VKA
Drug-eluting stents: undeﬁned
None
VKA þ APT vs. VKA alone:
HR: 1.12 (95% CI: 0.94–1.34)
High risk
HR: 1.50 (95% CI: 1.23–1.82) comparing
aspirin þ VKA vs. VKA alone
ORBIT AF Registry
(N ¼ 7,347)
2010–2011
Broadly inclusive U.S.
multicenter site-
based registry
AF on OAC;
<10% drug-eluting stents;
<50% with CAD
None
MI: w0.4% in both groups
High risk
Adjusted HR: 1.53 (95% CI: 1.20–1.96)
compared with OAC alone
WOEST Trial
(N ¼ 573)
2008–2011
Randomized European
multicenter
clinical trial
Elective and urgent coronary
intervention: randomized
to aspirin, clopidogrel, VKA
vs. clopidogrel and VKA
None
Stent thrombosis
1.4 vs. 3.2%; p ¼ 0.17
High risk
19% for clopidogrel and VKA vs. 44% for
aspirin, clopidogrel and VKA (HR 0.36;
95% CI: 0.26–0.50; p < 0.0001)
ACS ¼ acute coronary syndrome(s); AF ¼ atrial ﬁbrillation; APT ¼ antiplatelet therapy; CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction;
OAC ¼ oral anticoagulant therapy; PCI ¼ percutaneous coronary intervention; VKA ¼ vitamin K antagonist.
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1438about platelet inhibition in patients with CAD who
are taking oral anticoagulant agents.
THE ASSAULT ON ASPIRIN IN CONJUNCTION WITH
ORAL ANTICOAGULANT AGENTS. The indications
for and beneﬁt of oral anticoagulation are clear and
consistent across a broad spectrum of patients with
atrial ﬁbrillation who are at moderate to high risk of
embolic events (13,14). Recent guideline statements
support the conclusions of the CORONOR registry: the
coexistence of atrial ﬁbrillation with CAD is neither
an excuse for stopping oral anticoagulation, nor an
indication for continuing antiplatelet therapy. An
example from the 2006 American College of Cardio-
logy/American Heart Association Atrial Fibrillation
management guidelines states, “For most patients
with atrial ﬁbrillation who have stable CAD, warfarin
alone (target INR 2.0-3.0) should provide satisfactory
antithrombotic prophylaxis against both cerebral and
myocardial ischemic events” (14). More recently, the
WOEST (What is the Optimal Antiplatelet and Anti-
coagulant Therapy in Patients with Oral Anti-
coagulation and Coronary Stenting) trial suggested
that even the foundational principle of dual anti-
platelet therapy after implanting a drug-eluting stent
is wrong; the combination of clopidogrel and warfarin
does not increase the risk of ischemic events and
lessens the risk of major bleeding dramatically (12).
Although there is a broad chorus of guidelines,
registries, and trial data that all say the same thing,
this entire area may be less clear than these strong
concluding statements. Table 1 looks uniformly con-
clusive, but closer inspection highlights two striking
limitations: heterogeneity of focus and lack of powerto form ﬁrm conclusions. Some studies focus on
the early pathophysiological response after coronary
revascularization or acute myocardial infarction
(12,15). Can the WOEST trial really show that one
antithrombotic regimen is noninferior to another
regimen with respect to stent thrombosis in 536 ran-
domized patients (12)? If so, then why did the DAPT
(Dual Antiplatelet Therapy) trial require >20,000 pa-
tients to demonstrate the risk associated with
different durations of oral antiplatelet therapy after
stenting (16)? It seems implausible that the WOEST
trial can claim it is safe to halt aspirin therapy early
after a revascularization procedure.
The CORONOR registry provides valuable insight
into the bleeding risk of patients who continue
aspirin with vitamin K antagonists; like WOEST, the
power to analyze infrequent events (i.e., stent
thrombosis) may be limited. In CORONOR, <500 pa-
tients who had an indication for oral anticoagulation
were studied. The 95% conﬁdence intervals for pre-
dicting the excess hazard ratio of ischemic events
associated with aspirin cessation in this relatively
small group of patients was necessarily wide (0.58 to
2.27). Thus, even if it could be argued that multivar-
iable analysis controls for the differences between
patients getting aspirin and those who are not, the
strong conclusions applied to clinical practice should
be cautioned by the small sample size. A Danish reg-
istry also concluded that aspirin should be dis-
continued in patients with stable CAD on oral
anticoagulant agents (5); like CORONER, this registry
was a large (N ¼ 8,700) multicenter trial, and appro-
priate multivariable analyses were performed to try to
J A C C V O L . 6 4 , N O . 1 4 , 2 0 1 4 Dauerman
O C T O B E R 7 , 2 0 1 4 : 1 4 3 7 – 4 0 Aspirin in Stable Coronary Disease
1439control for differences in patients on aspirin versus
patients off aspirin. However, the strong conclusion
was at odds with the clinical practice of the majority
of the Danish population sampled; of the 8,700 pa-
tients with stable CAD and atrial ﬁbrillation, only
11% received the recommended regimen of warfarin
alone. Perhaps 90% of clinicians are practicing in-
correctly; perhaps, there are uncontrolled for con-
founders (i.e., clinicians continue aspirin in patients
with drug-eluting stents or more extensive CAD) that
might explain this variance in practice and its asso-
ciated risks.
Other atrial ﬁbrillation registries also provide
similar conclusions: aspirin cessation is not an
ischemic risk, but it can cause major bleeding in the
setting of oral anticoagulation. As shown in Table 1,
the ORBIT AF (Outcomes Registry for Better Infor-
med Treatment of Atrial Fibrillation) study was a
large registry of outpatients in stable condition with
chronic atrial ﬁbrillation that suggested that myo-
cardial infarction is rare and similar (0.4% per year) in
patients treated with aspirin or in patients who
stopped aspirin and are now on oral anticoagulant
agents (7). However, the focus was not on CAD
patients in stable condition—rather, the focus
was atrial ﬁbrillation patients—the stable CAD popu-
lation was a subgroup analysis of the study. Impor-
tantly, <10% of patients in this study had previous
drug-eluting stents. The total population of patients
with previous drug-eluting stents who received oral
anticoagulation in ORBIT AF was 115 patients. Unfor-
tunately, it was hard to provide ﬁrm guidance for
clinical decision-making from an underpowered sub-
group analyses of observational studies.
ASPIRIN AND THE ART OF STABLE CAD MAIN-
TENANCE. The absence of clear data does not pro-
vide any relief from clinical decision-making.
CORONOR, ORBIT AF, and other registry studies have
provided some actionable messages:
1. There is no evidence that inhibition of platelet
activation provides anything but harm in patients
with atrial ﬁbrillation who do not have CAD. Thismay seem obvious, but ORBIT AF demonstrated
that nearly 40% of patients who received a com-
bination of aspirin and oral anticoagulant agents
had no evidence of CAD. Stop the aspirin in these
patients.
2. CORONOR showed that the risk of major bleeding
in patients with stable CAD was lower than that
seen in the inpatient setting, and that the bleeding
was primarily gastrointestinal in nature. In pa-
tients with a history of gastrointestinal bleeding
and CAD, increased vigilance and prophylactic
measures are warranted. If a patient with atrial
ﬁbrillation and stable CAD is at high risk for
gastrointestinal bleeding, aspirin cessation, rather
than warfarin cessation, may be recommended.
3. In patients with acute and stable CAD who have
undergone revascularization with coronary stents,
it is certain that continuing aspirin increases the
bleeding risk in patients who require oral anti-
coagulation. However, there are no adequately
powered trials or large dedicated registries to
answer the question of whether aspirin cessation is
safe in this particular group.
Thus, tomorrow in clinic, I will continue to give a
platelet activation inhibitor, aspirin 81 mg/day, to
many of my patients in stable condition with CAD
and atrial ﬁbrillation; this will be especially true for
those patients who have ﬁrst-generation drug-eluting
stents, who had platelet activation leading to very
late stent thrombosis which is a rare, but devastating
risk (17). In selected CAD patients in stable condition
with atrial ﬁbrillation identiﬁed by CORONOR as at
high risk for bleeding, these registry observations will
be heeded: stop the aspirin, continue the warfarin,
and use the art of clinical medicine to guide decisions
where clear information remains wanting.
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